Randomized Phase II Trial of Chemoembolization and Sorafenib
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The study will be a single-center, randomized Phase II study of conventional TACE in
combination with sorafenib, given either continuously or sequentially, in patients with
unresectable HCC. The primary variables will be tumor response (by MR Imaging) and plasma
VEGF levels, prior to and after cTACE.